Vertex Pharmaceuticals, Inc. (NASDAQ: VRTX) is 21.25% higher on its value in year-to-date trading and has touched a low of $340.83 and a high of $510.64 in the current 52-week trading range. The question becomes, what are the chances the stock will continue to grow shareholders’ wealth in the market. Here’s what analysts think will happen to its price in the coming time. The VRTX stock was last observed hovering at around $489.73 in the last trading session, with the day’s gains setting it 3.62%.
Currently trading at $493.35, the stock is 3.00% and 2.40% above its SMA20 and SMA50 respectively. However, with a daily trading volume of 0.7 million and changing 0.74% at the moment leaves the stock 14.56% off its SMA200. VRTX registered 40.45% gain for a year compared to 6-month gain of 17.26%.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
The stock witnessed a -0.48% loss in the last 1 month and extending the period to 3 months gives it a 11.35%, and is 2.80% up over the last 5 days. If we measure the stock’s price variations over the week and the month, we find that the volatility rates stand at 1.65% over the week and 2.05% over the month.
Vertex Pharmaceuticals, Inc. (VRTX) has around 5400 employees, a market worth around $127.33B and $10.32B in sales. Fwd P/E is 26.41. Profit margin for the company is -4.75%. Distance from 52-week low is 44.75% and -3.39% from its 52-week high. The company has generated returns on investments over the last 12 months (-3.12%).
The EPS is expected to shrink by -97.83% this year
2228.0 institutions hold shares in Vertex Pharmaceuticals, Inc. (VRTX), with institutional investors hold 95.65% of the company’s shares. The shares outstanding are 257.70M, and float is at 257.43M with Short Float at 1.72%. Institutions hold 95.57% of the Float.
The top institutional shareholder in the company is CAPITAL WORLD INVESTORS with over 26.71 million shares valued at $12.52 billion. The investor’s holdings represent 10.3439 of the VRTX Shares outstanding. As of 2024-06-30, the second largest holder is VANGUARD GROUP INC with 22.98 million shares valued at $10.77 billion to account for 8.8983 of the shares outstanding. The other top investors are BLACKROCK INC. which holds 21.31 million shares representing 8.2542 and valued at over $9.99 billion, while STATE STREET CORP holds 4.5415 of the shares totaling 11.73 million with a market value of $5.5 billion.
Vertex Pharmaceuticals, Inc. (VRTX) Insider Activity
The most recent transaction is an insider sale by Bhatia Sangeeta N., the company’s Director. SEC filings show that Bhatia Sangeeta N. sold 1,292 shares of the company’s common stock on Aug 08 ’24 at a price of $466.29 per share for a total of $0.6 million. Following the sale, the insider now owns 4435.0 shares.
Vertex Pharmaceuticals, Inc. disclosed in a document filed with the SEC on Aug 07 ’24 that Bozic Carmen (EVP and CMO) sold a total of 2,280 shares of the company’s common stock. The trade occurred on Aug 07 ’24 and was made at $476.75 per share for $1.09 million. Following the transaction, the insider now directly holds 23259.0 shares of the VRTX stock.
Still, SEC filings show that on Aug 08 ’24, Bhatia Sangeeta N. (Director) Proposed Sale 1,292 shares at an average price of $466.29 for $0.6 million. The insider now directly holds shares of Vertex Pharmaceuticals, Inc. (VRTX).
